Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies

γ‐Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease by reducing pathogenic amyloid‐β (Aβ) peptide production. Three phase I studies (NCT02316756, NCT02407353, and NCT02440100) investigated the safety/tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Jae Eun, Carrieri, Charles, Dela Cruz, Fernando, Fullerton, Terence, Hajos‐Korcsok, Eva, He, Ping, Kantaridis, Constantino, Leurent, Claire, Liu, Richann, Mancuso, Jessica, Mendes da Costa, Laure, Qiu, Ruolun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977340/
https://www.ncbi.nlm.nih.gov/pubmed/31314925
http://dx.doi.org/10.1002/cpt.1570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977340/
https://www.ncbi.nlm.nih.gov/pubmed/31314925
http://dx.doi.org/10.1002/cpt.1570

Ejemplares similares